ANZSA Director, A/Prof David Gyorki, together with his team successfully received a grant worth almost AUD$1 million from an MRFF Grant for STRASS 2 trial. Read more about it.
The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin) for Australian patients. Read more...
This is the results summary of the EWING 2008 - a joint study of the European and North American Ewing sarcoma study groups.
Great news for all Australian patients diagnosed with rhabdomyosarcoma (RMS). The Chris O’Brien Lifehouse (NSW) is the first sarcoma specialist centre in Australia to start patient recruitment for the all-important clinical trial – FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma.
Read our tribute to our great friend, mentor and colleague, Professor Martin Tattersall AO.
ANZSA Virtual ASM 2020 is scheduled for 8-9 October that will allow the sarcoma community to share updates and progress. Read the details here.
Dr Denise Caruso was featured in this podcast episode where she spoke about sarcoma, clinical trials and what ANZSA does. Have a listen!
The Johanna Sewell Sarcoma Research Grant was awarded to Dr James Blackburn from the Garvan Institute of Medical Research who will look to improve fusion gene detection and immune response assessment in sarcoma patients. Read more...